참고문헌 (23)

1. Bang, Yung-Jue, Van Cutsem, Eric, Fuchs, Charles S., Ohtsu, Atsushi, Tabernero, Josep, Ilson, David H., Hyung, Woo Jin, Strong, Vivian E., Goetze, Thorsten Oliver, Yoshikawa, Takaki, Tang, Laura H., Hwang, Peggy May Tan, Shitara, Kohei. KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.36, no._suppl15, TPS4136-TPS4136.

   상세보기

2. Janjigian, Yelena Y., Van Cutsem, Eric, Muro, Kei, Wainberg, Zev A., Al-Batran, Salah-Eddin, Hyung, Woo Jin, Molena, Daniela, Evans, Brent, Ruscica, Dario, Robbins, Scott H., Negro, Alejandra, Tabernero, Josep. MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer-A randomized, double-blind, placebo-controlled, phase 3 study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.39, no.15, TPS4151-TPS4151.

   상세보기

3. Al-Batran, S-E., Lorenzen, S., Thuss-Patience, P.C., Schenk, M., Goekkurt, E., Hofheinz, R.D., Kretzschmar, A., Heuer, V., Bolling, C., Haag, G.M., Angermeier, S., Fischer von Weikersthal, L., Bechstein, W.O., Wicki, A., Siebenhüner, A., Waberer, L., Irahara, N., Pauligk, C., Götze, T.O., Homann, N.. 1494P Updated safety data of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma - A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK. Annals of oncology : official journal of the European Society for Medical Oncology, vol.31, no.suppl4, S927-S928.

   상세보기

4. Smyth, Elizabeth Catherine, Knoedler, Maren Kristina, Nilsson, Magnus, Wagner, Anna Dorothea, Moehler, Markus H., van Grieken, Nicole C.T., Giraut, Anne, Mauer, Murielle E., Lordick, Florian. EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): An open-label randomized controlled phase II study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.38, no.4, TPS467-TPS467.

   상세보기

5. Janjigian, Yelena Y, Shitara, Kohei, Moehler, Markus, Garrido, Marcelo, Salman, Pamela, Shen, Lin, Wyrwicz, Lucjan, Yamaguchi, Kensei, Skoczylas, Tomasz, Campos Bragagnoli, Arinilda, Liu, Tianshu, Schenker, Michael, Yanez, Patricio, Tehfe, Mustapha, Kowalyszyn, Ruben, Karamouzis, Michalis V, Bruges, Ricardo, Zander, Thomas, Pazo-Cid, Roberto, Hitre, Erika, Feeney, Kynan, Cleary, James M, Poulart, Valerie, Cullen, Dana, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun, Ajani, Jaffer A. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet, vol.398, no.10294, 27-40.

   상세보기

6. Shitara, Kohei, Ajani, Jaffer A., Moehler, Markus, Garrido, Marcelo, Gallardo, Carlos, Shen, Lin, Yamaguchi, Kensei, Wyrwicz, Lucjan, Skoczylas, Tomasz, Bragagnoli, Arinilda Campos, Liu, Tianshu, Tehfe, Mustapha, Elimova, Elena, Bruges, Ricardo, Zander, Thomas, de Azevedo, Sergio, Kowalyszyn, Ruben, Pazo-Cid, Roberto, Schenker, Michael, Cleary, James M., Yanez, Patricio, Feeney, Kynan, Karamouzis, Michalis V., Poulart, Valerie, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun, Janjigian, Yelena Y.. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature, vol.603, no.7903, 942-948.

   상세보기

7. Kang, Yoon-Koo, Chen, Li-Tzong, Ryu, Min-Hee, Oh, Do-Youn, Oh, Sang Cheul, Chung, Hyun Cheol, Lee, Keun-Wook, Omori, Takeshi, Shitara, Kohei, Sakuramoto, Shinichi, Chung, Ik-Joo, Yamaguchi, Kensei, Kato, Ken, Sym, Sun Jin, Kadowaki, Shigenori, Tsuji, Kunihiro, Chen, Jen-Shi, Bai, Li-Yuan, Oh, Sung-Yong, Choda, Yasuhiro, Yasui, Hisateru, Takeuchi, Kentaro, Hirashima, Yoshinori, Hagihara, Shunsuke, Boku, Narikazu. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, vol.23, no.2, 234-247.

   상세보기

8. Xu, J., Jiang, H., Pan, Y., Gu, K., Cang, S., Han, L., Shu, Y., Li, J., Zhao, J., Pan, H., Luo, S., Qin, Y., Guo, Q., Bai, Y., Ling, Y., Guo, Y., Li, Z., Liu, Y., Wang, Y., Zhou, H.. LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study. Annals of oncology : official journal of the European Society for Medical Oncology, vol.32, no.suppl5, S1331-.

   상세보기

9. Xu, Rui-hua, Arkenau, Hendrik-Tobias, Bang, Yung-Jue, Denlinger, Crystal S., Kato, Ken, Tabernero, Josep, Wang, Jin, Li, Jiang, Castro, Henry, Moehler, Markus H.. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.38, no.4, TPS458-TPS458.

   상세보기

10. Shitara, Kohei, Van Cutsem, Eric, Bang, Yung-Jue, Fuchs, Charles, Wyrwicz, Lucjan, Lee, Keun-Wook, Kudaba, Iveta, Garrido, Marcelo, Chung, Hyun Cheol, Lee, Jeeyun, Castro, Hugo Raul, Mansoor, Wasat, Braghiroli, Maria Ignez, Karaseva, Nina, Caglevic, Christian, Villanueva, Luis, Goekkurt, Eray, Satake, Hironaga, Enzinger, Peter, Alsina, Maria, Benson, Al, Chao, Joseph, Ko, Andrew H., Wainberg, Zev A., Kher, Uma, Shah, Sukrut, Kang, S. Peter, Tabernero, Josep. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer : The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA oncology, vol.6, no.10, 1571-.

    상세보기

11. Moehler, Markus, Dvorkin, Mikhail, Boku, Narikazu, Özgüroğlu, Mustafa, Ryu, Min-Hee, Muntean, Alina S., Lonardi, Sara, Nechaeva, Marina, Bragagnoli, Arinilda C., Coşkun, Hasan S., Cubillo Gracian, Antonio, Takano, Toshimi, Wong, Rachel, Safran, Howard, Vaccaro, Gina M., Wainberg, Zev A., Silver, Matthew R., Xiong, Huiling, Hong, Janet, Taieb, Julien, Bang, Yung-Jue. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.39, no.9, 966-977.

    상세보기

12. Janjigian, Yelena Y., Kawazoe, Akihito, Yanez, Patricio Eduardo, Luo, Suxia, Lonardi, Sara, Kolesnik, Oleksii, Barajas, Olga, Bai, Yuxian, Shen, Lin, Tang, Yong, Wyrwicz, Lucjan, Shitara, Kohei, Qin, Shukui, Van Cutsem, Eric, Tabernero, Josep, Li, Lie, Shih, Chie-Schin, Bhagia, Pooja, Chung, Hyun Cheol Cheol. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.39, no.15, 4013-4013.

    상세보기

13. Stein, A., Paschold, L., Tintelnot, J., Goekkurt, E., Thuss-Patience, P.C., Lorenzen, S., Ettrich, T.J., Knorrenschild, J. Riera, Jacobasch, L., Kretzschmar, A., Kubicka, S., Al-Batran, S-E., Reinacher-Schick, A., Pink, D., Sinn, M., Lindig, U., Hinke, A., Hegewisch Becker, S., Binder, M.. LBA54 Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217). Annals of oncology : official journal of the European Society for Medical Oncology, vol.32, no.suppl5, S1331-.

    상세보기

14. Shitara, Kohei, Özgüroğlu, Mustafa, Bang, Yung-Jue, Di Bartolomeo, Maria, Mandalà, Mario, Ryu, Min-Hee, Fornaro, Lorenzo, Olesiński, Tomasz, Caglevic, Christian, Chung, Hyun C, Muro, Kei, Goekkurt, Eray, Mansoor, Wasat, McDermott, Raymond S, Shacham-Shmueli, Einat, Chen, Xinqun, Mayo, Carlos, Kang, S Peter, Ohtsu, Atsushi, Fuchs, Charles S, Lerzo, Guillermo, O'Connor, Juan Manuel, Mendez, Guillermo Ariel, Lynam, James, Tebbutt, Niall, Wong, Mark, Strickland, Andrew, Karapetis, Chris, Goldstein, David, Vasey, Paul, Van Laethem, Jean-Luc, Van Cutsem, Eric, Berry, Scott, Vincent, Mark, Muller, Bettina, Rey, Felipe, Zambrano, Angela, Guerra, Joaquin, Krogh, Merete, Baeksgaard, Lene, Yilmaz, Mette, Elme, Anneli, Magi, Andrus, Auvinen, Paivi, Alanko, Tuomo, Moehler, Markus, Kunzmann, Volker, Seufferlein, Thomas, Thuss-Patience, Peter, Goekkurt, Eray, Hoehler, Thomas, Haag, Georg, Al-Batran, Salah-Eddin, Castro,. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. The Lancet, vol.392, no.10142, 123-133.

    상세보기

15. Högner, Anica, Breithaupt, Kirstin, Stein, Alexander, Hinke, Axel, Lorenz, Mario, Al-Batran, Salah-Eddin, Thuss-Patience, Peter C.. RAP: A phase II trial with ramucirumab, avelumab, and paclitaxel as second line treatment in gastro-esophageal adenocarcinoma of the arbeitsgemeinschaft internistische onkologie (AIO).. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.37, no.15, TPS4148-TPS4148.

    상세보기

16. Catenacci, Daniel V T, Kang, Yoon-Koo, Park, Haeseong, Uronis, Hope E, Lee, Keun-Wook, Ng, Matthew C H, Enzinger, Peter C, Park, Se Hoon, Gold, Philip J, Lacy, Jill, Hochster, Howard S, Oh, Sang Cheul, Kim, Yeul Hong, Marrone, Kristen A, Kelly, Ronan J, Juergens, Rosalyn A, Kim, Jong Gwang, Bendell, Johanna C, Alcindor, Thierry, Sym, Sun Jin, Song, Eun-Kee, Chee, Cheng Ean, Chao, Yee, Kim, Sunnie, Lockhart, A Craig, Knutson, Keith L, Yen, Jennifer, Franovic, Aleksandra, Nordstrom, Jeffrey L, Li, Daner, Wigginton, Jon, Davidson-Moncada, Jan K, Rosales, Minori Koshiji, Bang, Yung-Jue. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial. The Lancet. Oncology, vol.21, no.8, 1066-1076.

    상세보기

17. Catenacci, Daniel V.T., Rosales, Minori Koshiji, Chung, Hyun Cheol, Yoon, Harry H., Shen, Lin, Moehler, Markus H., Kang, Yoon-Koo. Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.39, no.3, TPS264-TPS264.

    상세보기

18. Kang, Yoon-Koo, Boku, Narikazu, Satoh, Taroh, Ryu, Min-Hee, Chao, Yee, Kato, Ken, Chung, Hyun Cheol, Chen, Jen-Shi, Muro, Kei, Kang, Won Ki, Yeh, Kun-Huei, Yoshikawa, Takaki, Oh, Sang Cheul, Bai, Li-Yuan, Tamura, Takao, Lee, Keun-Wook, Hamamoto, Yasuo, Kim, Jong Gwang, Chin, Keisho, Oh, Do-Youn, Minashi, Keiko, Cho, Jae Yong, Tsuda, Masahiro, Chen, Li-Tzong. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, vol.390, no.10111, 2461-2471.

    상세보기

19. 10.3410/f.732851580.793549623 

    

20. Bang, Y -J, Ruiz, E Yañez, Van Cutsem, E, Lee, K -W, Wyrwicz, L, Schenker, M, Alsina, M, Ryu, M -H, Chung, H -C, Evesque, L, Al-Batran, S -E, Park, S H, Lichinitser, M, Boku, N, Moehler, M H, Hong, J, Xiong, H, Hallwachs, R, Conti, I, Taieb, J. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Annals of oncology : official journal of the European Society for Medical Oncology, vol.29, no.10, 2052-2060.

    상세보기

21. Yoon, Harry H., Jin, Zhaohui, Kour, Oudom, Shitara, Kohei, Gibson, Michael K., Prokop, Larry, Kang, Yoon-Koo, Shi, Qian, Ajani, Jaffer A.. Association of magnitude and consistency of PD-L1 expression and other variables associated with benefit from immune checkpoint inhibition (ICI): Systematic review and meta-analysis of 14 phase 3 trials in advanced gastroesophageal cancer (GEC).. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.40, no.4, 344-344.

    상세보기

22. Pietrantonio, F., Randon, G., Di Bartolomeo, M., Luciani, A., Chao, J., Smyth, E.C., Petrelli, F.. Predictive role of microsatellite instability for of PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. Esmo open, vol.6, no.1, 100036-.

    상세보기

23. Marabelle, Aurélien, Fakih, Marwan, Lopez, Juanita, Shah, Manisha, Shapira-Frommer, Ronnie, Nakagawa, Kazuhiko, Chung, Hyun Cheol, Kindler, Hedy L, Lopez-Martin, Jose A, Miller Jr, Wilson H, Italiano Jr, Antoine, Kao Jr, Steven, Piha-Paul Jr, Sarina A, Delord Jr, Jean-Pierre, McWilliams Jr, Robert R, Fabrizio Jr, David A, Aurora-Garg Jr, Deepti, Xu Jr, Lei, Jin Jr, Fan, Norwood Jr, Kevin, Bang Jr, Yung-Jue. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. The Lancet. Oncology, vol.21, no.10, 1353-1365.

    상세보기